Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454–63. https://doi.org/10.1002/prca.201300095.

Article  CAS  PubMed  Google Scholar 

Liu R, Li H, Liu L, Yu J, Ren X. Fibroblast activation protein: A potential therapeutic target in cancer. Cancer Biol Ther. 2012;13:123–9. https://doi.org/10.4161/cbt.13.3.18696.

Article  CAS  PubMed  Google Scholar 

Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA. 1990;87:7235–9. https://doi.org/10.1073/pnas.87.18.7235.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu K, Wang L, Wu H, Huang S, Tian Y, Wang Q, et al. [(18)F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [(68)Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2022;49:2833–43. https://doi.org/10.1007/s00259-021-05646-z.

Article  CAS  PubMed  Google Scholar 

Imlimthan S, Moon ES, Rathke H, Afshar-Oromieh A, Rösch F, Rominger A, et al. New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress. Pharmaceuticals (Basel, Switzerland). 2021;14. https://doi.org/10.3390/ph14101023.

Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, et al. Biodistribution, pharmacokinetics, dosimetry of [(68)Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [(18)F]F-FDG PET/CT in patients with various cancers. Eur J Nucl Med Mol Imaging. 2021;48:1915–31. https://doi.org/10.1007/s00259-020-05132-y.

Article  CAS  PubMed  Google Scholar 

Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med. 2018;59:1415–22. https://doi.org/10.2967/jnumed.118.210443.

Article  CAS  PubMed  Google Scholar 

Jansen K, Heirbaut L, Verkerk R, Cheng JD, Joossens J, Cos P, et al. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). J Med Chem. 2014;57:3053–74. https://doi.org/10.1021/jm500031w.

Article  CAS  PubMed  Google Scholar 

Jansen K, Heirbaut L, Cheng JD, Joossens J, Ryabtsova O, Cos P, et al. Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. ACS Med Chem Lett. 2013;4:491–6. https://doi.org/10.1021/ml300410d.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [(18)F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2021;48:73–86. https://doi.org/10.1007/s00259-020-04940-6.

Article  PubMed  Google Scholar 

Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820–32. https://doi.org/10.1007/s00259-020-04769-z.

Article  PubMed  Google Scholar 

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60:801–5. https://doi.org/10.2967/jnumed.119.227967.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Song W, Qin C, Liu F, Lan X. Non-malignant findings of focal (68)Ga-FAPI-04 uptake in pancreas. Eur J Nucl Med Mol Imaging. 2021;48:2635–41. https://doi.org/10.1007/s00259-021-05194-6.

Article  CAS  PubMed  Google Scholar 

Li H, Ye S, Li L, Zhong J, Yan Q, Zhong Y, et al. (18)F- or (177)Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention. Eur J Nucl Med Mol Imaging. 2022;49:2705–15. https://doi.org/10.1007/s00259-022-05757-1.

Article  CAS  PubMed  Google Scholar 

Hu K, Li J, Wang L, Huang Y, Li L, Ye S, et al. Preclinical evaluation and pilot clinical study of [(18)F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts. Acta pharmaceutica Sinica B. 2022;12:867–75. https://doi.org/10.1016/j.apsb.2021.09.032.

Article  CAS  PubMed  Google Scholar 

Wang S, Zhou X, Xu X, Ding J, Liu S, Hou X, et al. Clinical translational evaluation of Al(18)F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2021;48:4259–71. https://doi.org/10.1007/s00259-021-05470-5.

Article  CAS  PubMed  Google Scholar 

Jiang X, Wang X, Shen T, Yao Y, Chen M, Li Z, et al. FAPI-04 PET/CT Using [(18)F]AlF Labeling Strategy: Automatic Synthesis, Quality Control, and In Vivo Assessment in Patient. Front Oncol. 2021;11:649148. https://doi.org/10.3389/fonc.2021.649148.

Article  PubMed  PubMed Central  Google Scholar 

Giesel FL, Adeberg S, Syed M, Lindner T, Jiménez-Franco LD, Mavriopoulou E, et al. FAPI-74 PET/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. J Nucl Med. 2021;62:201–7. https://doi.org/10.2967/jnumed.120.245084.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toms J, Kogler J, Maschauer S, Daniel C, Schmidkonz C, Kuwert T, et al. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an (18)F-Labeled FAP Inhibitor. J Nucl Med. 2020;61:1806–13. https://doi.org/10.2967/jnumed.120.242958.

Article  CAS  PubMed  Google Scholar 

Huang J, Fu L, Hu K, Huang S, Han Y, Lin R, et al. Automatic Production and Preliminary PET Imaging of a New Imaging Agent [(18)F]AlF-FAPT. Front Oncol. 2021;11:802676. https://doi.org/10.3389/fonc.2021.802676.

Article  PubMed  Google Scholar 

Schottelius M, Wester HJ, Reubi JC, Senekowitsch-Schmidtke R, Schwaiger M. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. Bioconjug Chem. 2002;13:1021–30. https://doi.org/10.1021/bc0200069.

Article  CAS  PubMed  Google Scholar 

Niedermoser S, Chin J, Wängler C, Kostikov A, Bernard-Gauthier V, Vogler N, et al. In Vivo Evaluation of 18F-SiFAlin-Modified TATE: A Potential Challenge for 68Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET. J Nucl Med. 2015;56:1100–5. https://doi.org/10.2967/jnumed.114.149583.

Article  CAS  PubMed  Google Scholar 

Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Can Res. 2001;61:1781–5.

CAS  Google Scholar 

Xu M, Zhang P, Ding J, Chen J, Huo L, Liu Z. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy. J Nucl Med. 2022;63:952–8. https://doi.org/10.2967/jnumed.121.262533.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125–35. https://doi.org/10.1084/jem.20130110.

Article  CAS  PubMed  PubMed Central  Google Scholar